Gene
KDM5D
lysine demethylase 5D
Explore in graph →CI-GENE-00006810HGNC:11115 ENSG00000012817 NCBI 8284 CIViC Approved
Curated evidence
Clinical evidence (1)
CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 29863497
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| KDM5D Loss1 | ||||||||
| Berzosertib | Malignant Prostate Neoplasm | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID12684In prostate cancer cell lines with loss of the Y-linked histone demethylase KDM5D (knockdown in LNCaP and VCaP, or deletion in LNCaP-104R2 and E006AA), ATR signaling was activated, and the selective A… (full text at CIViC) PMID 29863497 · Komura et al., 2018 · Open in CIViC | civic |
Cohorts
Alteration frequency by cohort (0)
Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.
Data not yet available
No cohort frequency recorded for this gene.
Literature
Linked publications (0)
Data not yet available
No publication linked to this gene yet.